Journal
FRONTIERS IN ONCOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.673199
Keywords
humanized immune system; mouse model; tumor; immunotherapy; combination therapy
Categories
Funding
- National Natural Science Foundation Program of China [31772546, 32070532]
- Shaanxi Natural Science Foundation Program [2020PT-005]
Ask authors/readers for more resources
This article summarizes strategies for the development and use of HIS mice models in tumor immunotherapies, proposes a method of tumor identification and classification in HIS mice based on the tumor-infiltrating lymphocytes and PD-L1 expression, and suggests different combination treatment strategies to enhance the effect of immunotherapy.
Immunotherapy has been used as a first-line treatment for a variety of advanced tumors, allowing remarkable progress to be made in cancer treatment. Nonetheless, only a small number of patients can benefit from immune checkpoint inhibitor monotherapy. To improve the effect of immunotherapy, the underlying mechanism of combination therapy was investigated in the context of an intact human tumor immune microenvironment using mice with a human immune system (HIS) bearing human tumors. Herein, we summarize and discuss strategies for the development and use of HIS mice models in tumor immunotherapies. Most importantly, this review proposes a method of t11umor identification and classification in HIS mice based on the tumor-infiltrating lymphocytes and PD-L1 expression, and according to this classification, we propose different combination treatment strategies that can be utilized to enhance the effect of immunotherapy. Thus, we provide effective experimental schemes for tumor immunotherapy in HIS mice models.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available